Rhythm Pharmaceuticals (FRA:1RV) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1RV Rhythm Pharmaceuticals Inc FRA:1RV
59 GF Score
Price €96.00
GF Value €93.47
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1RV
59GF Score
Rhythm Pharmaceuticals Inc FRA:1RV
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rhythm Pharmaceuticals (FRA:1RV) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of €96.00 is trading 2.7% above its estimated GF Value™ of €93.47. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:1RV:

  • Short Ratio:
  • GF Value™: €93.47 vs. price of €96.00 (2.7% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:1RV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
59GF Score

Get the complete analysis for FRA:1RV

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€96.00
Price
€93.47
GF Value